The Technical Analyst
Spero Therapeutics Inc [SPRO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Spero Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.70% $1.430
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 77.07 mill |
| EPS: | 0.430 |
| P/E: | 3.33 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 53.89 mill |
| Avg Daily Volume: | 0.323 mill |
| RATING 2024-04-25 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 3.33 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.57x |
| Company: PE 3.33 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.350 - 1.530 ( +/- 6.25%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-01 | Keutzer Timothy | Buy | 239 731 | Common Stock |
| 2024-02-02 | Keutzer Timothy | Sell | 30 971 | Common Stock |
| 2024-02-02 | Mahadevia Ankit | Sell | 63 795 | Common Stock |
| 2024-02-01 | Joseph Tamara L | Buy | 239 731 | Common Stock |
| 2024-02-02 | Joseph Tamara L | Sell | 30 906 | Common Stock |
| INSIDER POWER |
|---|
| 59.03 |
| Last 96 transactions |
| Buy: 6 234 250 | Sell: 2 240 393 |
Forecast:
16:00 - $1.430
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.430
Forecast 2: 16:00 - $1.430
Forecast 3: 16:00 - $1.430
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.430 (0.70% ) |
| Volume | 0.168 mill |
| Avg. Vol. | 0.323 mill |
| % of Avg. Vol | 52.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SPRO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-03-13 16:01:00 - Press Release
Spero Therapeutics Announces Fourth Quarter And Full Year 2023 Operating Results And Provides A Business Update
Cambridge, mass., march 13, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced financial results for the fourth quarter and full year ended december 31, 2023, and provided a business update.
2024-03-06 08:05:00 - Press Release
Spero Therapeutics To Provide Business Update And Report Fourth Quarter And Full Year 2023 Financial Results On Wednesday, March 13, 2024
Cambridge, mass., march 06, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that it will host a conference call and live audio webcast on wednesday, march 13, 2024 at 4:30 p.m. et to report its fourth quarter and full year financial results and provide an update on its business and pipeline.
2024-02-28 08:05:00 - Press Release
Spero Therapeutics Announces Clearance Of Ind For Spr206 To Treat Mdr gram-negative Bacterial Infections
Cambridge, mass., feb. 28, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that it has received clearance by the u.s. food and drug administration (fda) for its investigational new drug (ind) application, to evaluate spr206 in a phase 2 clinical study. spr206 is a novel, intravenously (iv) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (habp/vabp) caused by mdr gram-negative bacterial infections.
2024-02-26 08:05:00 - Press Release
Spero Therapeutics To Present At Cowen's 44th Annual Healthcare Conference
Cambridge, mass., feb. 26, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro) (spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that sath shukla, president and chief executive officer of spero therapeutics, will present and be available for one-on-one meetings at the cowen 44th annual healthcare conference, which is taking place march 4-6, 2024, at the boston marriott copley place in boston, ma. details are as follows:
2024-01-31 16:05:00 - Press Release
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass., jan. 31, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that on january 29, 2024, the compensation committee of spero's board of directors approved the grant of an aggregate of 50,000 restricted stock unit awards (rsus) to a new employee under the spero therapeutics, inc. 2019 inducement equity incentive plan, as amended, or the 2019 inducement plan. the rsus are being granted as inducements material to the new employee becoming an employee of spero in accordance with nasdaq listing rule5635(c)(4).
Latest News
2024-03-13 18:10:15 - Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
Spero Therapeutics, Inc. (SPRO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to earnings of $0.55 per share a year ago.
2024-03-06 08:05:00 - GlobeNewsWire
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.
2024-02-26 08:05:00 - GlobeNewsWire
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place March 4-6, 2024, at the Boston Marriott Copley Place in Boston, MA. Details are as follows:
2023-11-13 19:05:08 - Seeking Alpha
Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath Shukla - Chief Executive Officer Kamal Hamed - Chief Medical Officer Steve Dipalma - Interim Chief Financial Officer and Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald Boobalan Pachaiyappan - H.C. Wainwright Good afternoon and welcome to the Spero Therapeutics Third Quarter 2023 Financial Results Conference Call.
2023-11-06 08:05:00 - GlobeNewsWire
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline.
2023-10-18 13:32:30 - Zacks Investment Research
All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy
Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-09-20 16:05:00 - GlobeNewsWire
Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference
CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at Cantor Fitzgerald's Global Healthcare 2023 Investor Conference, which will be held on September 26-28, 2023, at the Intercontinental Barclay Hotel in New York, NY. Details are as follows:
2023-09-06 08:05:00 - GlobeNewsWire
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place September 11-13, 2023, at the Lotte New York Palace Hotel in New York, NY. Details are as follows:
2023-08-29 13:31:14 - Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2023-08-29 09:01:32 - Zacks Investment Research
New Strong Buy Stocks for August 29th
SPRO, FBIZ, KNSL, BMI and FDUS have been added to the Zacks Rank #1 (Strong Buy) List on August 29, 2023.